Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
Project Summary/Abstract
Autoimmune diseases like type 1 diabetes arise through a breakdown in immune tolerance. We have now
come to understand that immune tolerance consists of a multi-layered network that keeps such untoward
responses in check. In this program project grant, three complementary teams will be working together to
further unravel how these checkpoints operate to improve our understanding of autoimmunity and ultimately
improve its treatment. This program project will have three highly collaborative and interactive projects headed
by Drs. Mark Anderson (Project 1), Jeff Bluestone (Project 2) and John Kappler (Project 3) along with two
scientific cores (Animal core and Molecular core). The major themes of the grant are:
1. The impact of central thymic tolerance on the T effector and Treg repertoire in T1D..
2. Insulin as a critical self-antigen specificity for both T effectors and T regulatory cells in T1D.
3. Peptide specificity of Tregulatory cells in T1D
4. Using peptide binding characteristics of islet antigens to improve bioassays and tolerance methods.
The long term objectives of this work is to improve our understanding of how T cell tolerance is controlled and
the further refining the specificity of the autoreactive T cell response in type 1 diabetes. The investigators will
be using state of the art tools in both animal models and in human subjects with type 1 diabetes. Results of
these studies will help further refine our understanding of autoimmunity and help improve methods for its
treatment and diagnosis.
Public Health Relevance Statement
Project Narrative
This is a program project grant that is centered on improving our understanding of how self-reactive T cells
develop or are kept in check in autoimmune type 1 diabetes. The results of the projects here will help improve
our ability to both detect and devise logical treatment strategies for this autoimmune disease.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
08-June-2016
Project End Date
31-May-2022
Budget Start Date
01-June-2020
Budget End Date
31-May-2022
Project Funding Information for 2020
Total Funding
$1,570,677
Direct Costs
$1,200,635
Indirect Costs
$370,042
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Allergy and Infectious Diseases
$1,570,677
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AI118688-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AI118688-05
Patents
No Patents information available for 5P01AI118688-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AI118688-05
Clinical Studies
No Clinical Studies information available for 5P01AI118688-05
News and More
Related News Releases
No news release information available for 5P01AI118688-05
History
No Historical information available for 5P01AI118688-05
Similar Projects
No Similar Projects information available for 5P01AI118688-05